Successive switching of antiretroviral therapy is associated with high psychological and physical burden

International Journal of STD and AIDS

Volumn 18, Issue 10, 2007, Pages 700-704

  Sherr, Lorraine ^a   Lampe, Fiona ^a   Norwood, Sally ^a   Leake Date, Heather ^b   Fisher, Martin ^b   Edwards, Simon ^c   Arthur, Gilly ^c   Anderson, Jane ^e   Zetler, Sarah ^e   Johnson, Margaret ^d   Harding, R ^f  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UK

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Royal Free Centre for HIV Medicine   (United Kingdom)

^e HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; ASIAN; BODY BUILD; CAUCASIAN; CONTROLLED STUDY; DISTRESS SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HEALTH BEHAVIOR; HETEROSEXUAL MALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERPERSONAL COMMUNICATION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NAUSEA; NEGRO; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SIDE EFFECT; SUICIDAL IDEATION; UNITED KINGDOM; ADULT; CROSS-SECTIONAL STUDY; DEMOGRAPHY; ETHNIC GROUP; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN IMMUNODEFICIENCY VIRUS; METHODOLOGY; PATHOPHYSIOLOGY; STATISTICS;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; DEMOGRAPHY; ENGLAND; ETHNIC GROUPS; FEMALE; HETEROSEXUALITY; HIV; HIV INFECTIONS; HOMOSEXUALITY; HUMANS; MALE; PATIENT COMPLIANCE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 38449109988     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/095646207782193821     Document Type: Article

References (27)

1. Nolan D, Reiss P, Mallal S. Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 2005;4:201-18
2. Martinez-Picado J, Negredo E, Ruiz L, et al. SWATCH Study Team. Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial. Ann Intern Med 2003;139:81-9
3. Katlama C, Fenske S, Gazzard B, et al. AZL30002 European study team. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med 2003;4:79-86
4. Moyle G. The switching spiral: a triumph of hope over benefit? AIDS Read 2002;12:147-50
5. Harding R, Molloy T, Easterbrook PE, Frame K, Higginson IJ. Is antiretroviral therapy associated with symptom prevalence and burden? Int J STD AIDS (in press)
6. Hansen BR, Haugaard SB, Iversen J, Nielsen JO, Andersen O. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004;36:244-53
7. John M, McKinnon EJ, James IR, et al. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 2003;33:29-33
8. Burton CT, Nelson MR, Hay P, Gazzard BG, Gotch FM, Imami N. Immunological and virological consequences of patient-directed antiretroviral therapy interruption during chronic HIV-1 infection. Clin Exp Immunol 2005;142:354-61
9. Allavena C, Le Moal G, Michau C, Chiffoleau A, Raffi F. Neuropsychiatric adverse events after switching from an antiretroviral regimen containing efavirenz without tenofovir to an efavirenz regimen containing tenofovir: a report of nine cases. Antivir Ther 2006;11:263-5
10. Bucher HC, Young J, Battegay M. Protease inhibitor-sparing simplified maintenance therapy: a need for perspective. J Antimicrob Chemother 2004;54:303-5. Epub 21 July 2004
11. Gil P, de Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin Infect Dis 2004;39:1024-9. Epub 8 September 2004
12. Leen CL. Perspectives on HAART: switch maintenance therapy. Int J STD AIDS 2003;14:577-82
13. Falkensammer B, El Attal R, Mullauer B, et al. Loss of zidovudine related mutations in the reverse transcriptase gene of HIV after switching therapy. Eur J Med Res 2002;7:379-86
14. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004;20:589-94
15. Domingo P, Labarga P, Palacios R, et al. RECOVER Study Group. Improvement of dyslipidemia in patients switching from stavudine to tenofovir: preliminary results. AIDS 2004;18:1475-8
16. Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis 2003;37:41-9. Epub 23 June 2003
17. Winston A, Pozniak A, Smith N, et al. Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals? AIDS 2004;18:572-4
18. Katlama C, Gazzard B, Mallolas J, et al. Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy. AIDS 2003;17:1855- 6
19. Miller LG, Golin CE, Hays RD, et al. Impact of antiretroviral regimen switches on adherence. HIV Clin Trials 2002;3:355-60
20. International Collaboration on HIV Optimism. HIV treatments optimism among gay men: an international perspective. J Acquir Immune Defic Syndr 2003;32:545-50
21. Portsmouth SD, Osorio J, McCormick K, Gazzard BG, Moyle GJ. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med 2005;6:185-90
22. Badia X, Podzamczer D, Moral I, et al. BestQol Study Group. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy. Antivir Ther 2004;9:979-85
23. Kirstein LM, Greenblatt RM, Anastos K, et al. Women's Interagency HIV Study Collaborative Research Group. Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2002;15:495-503
24. Elford J, Bolding G, Sherr L. High-risk sexual behaviour increases among London gay men between 1998 and 2001: what is the role of HIV optimism? AIDS 2002;16:1537-44
25. Kalichman SC, DiMarco M, Austin J, Luke W, DiFonzo K. Stress, social support, and HIV-status disclosure to family and friends among HIV-positive men and women. J Behav Med 2003;26:315-32
26. Chang VT, Hwang SS, Kasimis B, Thaler HT. Shorter symptom assessment instruments: the Condensed Memorial Symptom Assessment Scale (CMSAS). Cancer Invest 2004;22:526-36
27. The EuroQol Group. EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199-208